Following the BRUIN data in mantle cell lymphoma, will you routinely treat with pirtobrutinib following a covalent BTKi?  

Yes, this drug has demonstrated clear efficacy in a difficult-to-treat population and perhaps to date, the best safety data with a BTK inhibitor we have seen (low rates of cardiac, bleeding, and GI adverse events). There is a head-to-head study of pirtobrutinib versus covalent BTK inhibitors ongoing...

I have incorporated pirtobrutinib into my practice since its approval. I recommend this for treatment in patients who are progressing on covalent BTKi or who have had prior exposure to covalent BTKi with progression and received alternative therapies with further progression. I have used pirtobrutin...